Abstract

Thymosin Beta-4 (TB-4) is a 43-amino-acid, 4.9 kDa actin-sequestering peptide expressed ubiquitously in mammalian tissues. Its primary physiological role is regulation of the G-actin/F-actin equilibrium through 1:1 binding to monomeric actin. The N-terminal fragment Ac-LKKTETQ (TB-500) retains most of the actin-binding activity at lower molecular weight.

Molecular Background

Key characteristics of TB-4 and TB-500:

• TB-4 is encoded by the highly conserved X-chromosomal gene TMSB4X
• Central actin-binding motif: LKKTETQ (residues 17-23)
• High affinity G-actin binding (Kd ≈ 0.4 µM)
• Intrinsically disordered structure, adopts β-hairpin upon actin binding
• Both forms stable in plasma (t½ > 2 hours)

Research Applications

TB-500 has been investigated in laboratory settings for:

• Cell Migration Studies: Actin-mediated motility research
• Wound Healing: Dermal and corneal repair mechanisms
• Cardiac Research: Myocardial regeneration studies
• Anti-inflammatory Research: Inflammatory marker modulation
• Hair Biology: Follicle cycling and growth studies

Proposed Mechanisms

• Actin Sequestration: Lowering F-actin stress fibers to facilitate migration
• VEGF Induction: Angiogenesis promotion
• MMP Activation: Matrix remodeling processes
• NF-κB Inhibition: Anti-inflammatory effects
• PIN1 Binding: Isomerization of phosphorylated substrates

Preclinical Research Summary

Research models have included:

• Dermal wound closure models
• Corneal injury and regeneration
• Myocardial infarction models
• Spinal cord contusion studies
• Hair regrowth investigations

Technical Specifications

• Molecular Formula: C212H350N56O78S
• Molecular Weight: 4963.44 g/mol
• Purity: ≥99% (HPLC verified)
• Storage: Store lyophilized at -20°C

Current Research Status

TB-4 has progressed to early-phase human trials in specific applications such as wound healing and dry eye. The combination of mechanistic understanding and preclinical efficacy positions TB-500 as one of the more validated peptides in regenerative research.